NCT04958252View on ClinicalTrials.gov

A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

October 24, 2023

Study Completion Date

October 24, 2023

Conditions
Healthy
Interventions
DRUG

BI 1569912

BI 1569912

DRUG

Placebo

Placebo

Trial Locations (1)

130-0004

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY